A randomized clinical trial on improving osteopenia in postmenopausal women after two years of preventive treatment with alendronate; a dose of 35 mg per week is more effective or a dose of 70 mg?
Introduction: Osteoporosis is the most common metabolic bone disease worldwide. In this disease, the bone mass decreases and as it progresses, the risk of fracture increases. Osteopenia occurs in the early stages of bone loss. Studies on the effective dose for treatment of osteopenia have been contr...
Main Authors: | Mansoor Karimifar, Negar Botlani, Amirhossein Salari |
---|---|
Format: | Article |
Language: | English |
Published: |
Society of Diabetic Nephropathy Prevention
2020-01-01
|
Series: | Journal of Preventive Epidemiology |
Subjects: | |
Online Access: | https://jprevepi.com/PDF/jpe-5-e16.pdf |
Similar Items
-
The Findings of Bone Mineral Densitometry Following Preventive Treatment with Alendronate in Menopausal Women with Osteopenia; What is the Best Dose?
by: Mansour Karimifar, et al.
Published: (2020-12-01) -
Efficacy of alendronate and risedronate on bone mineral density in men with osteoporosis or osteopenia: a meta-analysis
by: Jehle, Karen, et al.
Published: (2013) -
The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
by: İlker Çorapçı, et al.
Published: (2004-03-01) -
REVIEW OF BASIC CLINICAL TRIALS OF ALENDRONATE
by: E G Zotkin, et al.
Published: (2010-03-01) -
Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels
by: Aly A.M. Shaalan, et al.
Published: (2020-05-01)